This is important, as IL-1-mediated and JAK-STAT signaling in iCAFs have motivated trials of adding IL-1R blockade to standard-of-care (FOLFIRINOX-based) chemotherapy72 (ClinicalTrials.gov: NCT02021422) and treating KPC mouse models with a JAK inhibitor decreases tumor size81. The gene discussed is IL1R1; the disease is neoplasm.